Zhuhai Rundu Pharmaceutical Co Ltd Class A (002923) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.036x

Based on the latest financial reports, Zhuhai Rundu Pharmaceutical Co Ltd Class A (002923) has a cash flow conversion efficiency ratio of 0.036x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥37.78 Million ≈ $5.53 Million USD) by net assets (CN¥1.05 Billion ≈ $153.24 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Zhuhai Rundu Pharmaceutical Co Ltd Class for the company's overall valuation and market capitalisation.

Zhuhai Rundu Pharmaceutical Co Ltd Class A - Cash Flow Conversion Efficiency Trend (2011–2025)

This chart illustrates how Zhuhai Rundu Pharmaceutical Co Ltd Class A's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Zhuhai Rundu Pharmaceutical Co Ltd Class A Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Zhuhai Rundu Pharmaceutical Co Ltd Class A ranked by their cash flow conversion efficiency. Explore Zhuhai Rundu Pharmaceutical Co Ltd Class (002923) cash flow quality to measure how well operating cash flow supports reported net income.

Company Cash Flow Conversion Efficiency
Sella Real Estate
TA:SLARL
0.021x
Bank Maspion Indonesia PT
JK:BMAS
0.015x
ZimVie Inc
NASDAQ:ZIMV
0.008x
Esso S.A.F.
PA:ES
-0.040x
Chenming Mold Industrial Corp
TW:3013
0.120x
Rural Funds Group
AU:RFF
0.011x
Hangzhou Dadi Haiyang Environmental Protection Co. Ltd.
SHE:301068
N/A
Smartoptics Group AS
OL:SMOP
0.323x

Annual Cash Flow Conversion Efficiency for Zhuhai Rundu Pharmaceutical Co Ltd Class A (2011–2025)

The table below shows the annual cash flow conversion efficiency of Zhuhai Rundu Pharmaceutical Co Ltd Class A from 2011 to 2025. View latest Zhuhai Rundu Pharmaceutical Co Ltd Class stock price today for real-time trading data and today's change.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 CN¥1.04 Billion
≈ $151.95 Million
CN¥104.41 Million
≈ $15.28 Million
0.101x -45.15%
2024-12-31 CN¥1.15 Billion
≈ $168.59 Million
CN¥211.19 Million
≈ $30.90 Million
0.183x +25.17%
2023-12-31 CN¥1.18 Billion
≈ $172.55 Million
CN¥172.68 Million
≈ $25.27 Million
0.146x +29.73%
2022-12-31 CN¥1.20 Billion
≈ $175.01 Million
CN¥135.01 Million
≈ $19.76 Million
0.113x -39.03%
2021-12-31 CN¥1.11 Billion
≈ $162.74 Million
CN¥205.91 Million
≈ $30.13 Million
0.185x -23.22%
2020-12-31 CN¥1.04 Billion
≈ $151.93 Million
CN¥250.35 Million
≈ $36.63 Million
0.241x +49.86%
2019-12-31 CN¥940.29 Million
≈ $137.59 Million
CN¥151.30 Million
≈ $22.14 Million
0.161x -11.85%
2018-12-31 CN¥871.29 Million
≈ $127.50 Million
CN¥159.04 Million
≈ $23.27 Million
0.183x +53.97%
2017-12-31 CN¥488.84 Million
≈ $71.53 Million
CN¥57.95 Million
≈ $8.48 Million
0.119x -49.82%
2016-12-31 CN¥398.19 Million
≈ $58.27 Million
CN¥94.07 Million
≈ $13.77 Million
0.236x +46.41%
2015-12-31 CN¥310.72 Million
≈ $45.47 Million
CN¥50.14 Million
≈ $7.34 Million
0.161x -23.98%
2014-12-31 CN¥273.31 Million
≈ $39.99 Million
CN¥58.01 Million
≈ $8.49 Million
0.212x +58.34%
2013-12-31 CN¥236.29 Million
≈ $34.58 Million
CN¥31.67 Million
≈ $4.63 Million
0.134x -61.82%
2012-12-31 CN¥199.43 Million
≈ $29.18 Million
CN¥70.01 Million
≈ $10.25 Million
0.351x +72.18%
2011-12-31 CN¥165.33 Million
≈ $24.19 Million
CN¥33.71 Million
≈ $4.93 Million
0.204x --

About Zhuhai Rundu Pharmaceutical Co Ltd Class A

SHE:002923 China Drug Manufacturers - Specialty & Generic
Market Cap
$535.14 Million
CN¥3.66 Billion CNY
Market Cap Rank
#12002 Global
#3466 in China
Share Price
CN¥10.92
Change (1 day)
-0.36%
52-Week Range
CN¥9.32 - CN¥17.35
All Time High
CN¥20.52
About

Zhuhai Rundu Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of chemical pharmaceutical preparations, APIs, and pharmaceutical intermediates in China and internationally. It offers FDF for cardiovascular, gastrointestinal, antibiotics, analgetic and antipyretics, anti-virus, endocrinology, and respiratory; and pellets for excipient, antiulcerative, diabetes … Read more